Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus.
about
Induction by anti-thymocyte globulins in kidney transplantation: a review of the literature and current usageSystemic and nonrenal adverse effects occurring in renal transplant patients treated with mTOR inhibitorsNew directions for rabbit antithymocyte globulin (Thymoglobulin(®)) in solid organ transplants, stem cell transplants and autoimmunityInduction therapy in heart transplantation: where are we now?Mammalian target of rapamycin (mTOR) inhibitors: potential uses and a review of haematological adverse effects.Five-year experience using sirolimus-based, calcineurin inhibitor-free immunosuppression in pediatric renal transplantation.Subclinical toxicity of calcineurin inhibitors in repeated protocol biopsies: an independent risk factor for chronic kidney allograft damageSafety and tolerability of the T-cell depletion protocol coupled with anakinra and etanercept for clinical islet cell transplantation.Mycophenolate mofetil: safety and efficacy in the prophylaxis of acute kidney transplantation rejection.Mycophenolic acid formulations in adult renal transplantation - update on efficacy and tolerability.Deferred pre-emptive switch from calcineurin inhibitor to sirolimus leads to improvement in GFR and expansion of T regulatory cell population: a randomized, controlled trial.Late kidney allograft loss: what we know about it, and what we can do about itA 12-month single arm pilot study to evaluate the efficacy and safety of sirolimus in combination with tacrolimus in kidney transplant recipients at high immunologic riskCyclosporine: a review.Genetic and clinical determinants of early, acute calcineurin inhibitor-related nephrotoxicity: results from a kidney transplant consortium.Chronic progressive calcineurin nephrotoxicity: an overstated concept.Developments in clinical islet, liver thoracic, kidney and pancreas transplantation in the last 5 years.Mycophenolate mofetil and sirolimus combination in renal transplantation.Sirolimus reduces polycystic liver volume in ADPKD patients.Long-term efficacy and safety of a calcineurin inhibitor-free regimen in live-donor renal transplant recipientsThe current role of calcineurin inhibitors in posttransplant immunosuppression?Can mTOR inhibitors reduce the risk of late kidney allograft failure?Calcineurin inhibitor-free immunosuppression in kidney transplantation.Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity.Minimizing immunosuppression, an alternative approach to reducing side effects: objectives and interim result.Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients.Recent developments in kidney transplantation--a critical assessment.Considerations in sirolimus use in the early and late post-transplant periods.Ten years experience with belatacept-based immunosuppression after kidney transplantation.Effects of metformin on hyperglycemia in an experimental model of tacrolimus- and sirolimus-induced diabetic rats.Prospects for mTOR inhibitor use in patients with polycystic kidney disease and hamartomatous diseases.Toxicity spectrum of inhibitors of mammalian target of rapamycin in organ transplantation: etiology, pathogenesis and treatment.Clinical application of mTORi based immunosuppression for renal transplantation in India.Meta-analysis of calcineurin-inhibitor-sparing regimens in kidney transplantation.An evaluation of sirolimus in renal transplantation.The role of Thymoglobulin induction in kidney transplantation: an update.Belatacept for prevention of acute rejection in adult patients who have had a kidney transplant: an update.Calcineurin inhibitor nephrotoxicity: a review and perspective of the evidence.Prevention of cytomegalovirus following solid organ transplantation: a literature review.Is it time to give up with calcineurin inhibitors in kidney transplantation?
P2860
Q26784305-7F096147-8610-4192-B834-A36CFAD5E96AQ26823023-5A53CA9A-1E22-4CF7-9198-26B984E377DDQ26823090-2690A59D-0EDF-49E3-B886-148C1DFF9E25Q26999269-3C62B217-F2CE-4D27-8734-745E4638D510Q33393707-D4A6F856-DAE6-4076-B37A-5F68F323D10BQ33394258-55B1D068-542F-4291-93B2-7B53319A3451Q33815032-C7BD73A5-909B-4DA8-B038-4A8A8A7380EBQ33848529-09FFFF30-55C1-42DA-8A16-8A32EC46221FQ34607590-460D8C15-5527-430C-BFD6-891A08ECBC61Q34611858-EB00C37E-8D48-44D5-B9AC-3C8A061646CBQ35022430-8700B60B-F09B-4725-BCD8-7D5AA3F317C5Q35153318-819051FC-3D52-4D76-8F05-B35ABF37AF6BQ35649082-13E69C4A-9536-46F8-B7F5-FADB9B3B643DQ35675934-F50BAE66-A79D-41CA-A4A5-D0A92820B379Q35823308-761F166E-48EF-4EF8-8D17-C43F4C911B65Q35929301-913C44EE-8C9B-47A6-85E5-91FBC72336B5Q36505718-024F0B3E-15C0-4B45-8710-3BA9FB8EF482Q36575992-5C22EF4A-089E-47BF-8E67-D45F891348EBQ36667245-969516AE-F4CE-401D-80F7-84D995C277DBQ36677625-6B2BCE5B-BD52-4E16-8838-9774ED2C158CQ36733784-B76F0808-8B20-4EDC-BBA5-94E675D20904Q36884566-1E69B22F-E188-4541-B305-D66BAD941323Q36889001-7630F04E-1874-4B6F-9756-4FCAD5B923DFQ37064446-53DA6C88-E4E8-474A-B2F3-64ECFC2A3B55Q37097694-15252555-0DB9-4018-94D0-9FE93A926011Q37176562-F8C65CCB-FA3F-4912-8AD5-2896EC757E3AQ37301840-37EF9954-21C8-46FA-A5FB-513DF5961537Q37517602-B9EDBF55-CB96-41F0-B929-A3D7BDBBA7CFQ37604599-55A9C144-A8C5-4673-838E-F5E778BB4605Q37683441-E799E924-5EA9-4068-B6A7-36BF461AE0ABQ37760379-F1DCB816-85B8-466A-8E1F-3888009E2C0DQ37873950-ABD08809-AC7F-4C8F-98AE-3332422D47F8Q37929851-E7FA4B9A-C5E6-462E-9ECD-5F6A53513A8FQ37939057-61A7E94D-5B86-4C9F-BAB5-CCF21E5B59B8Q38038696-4802C9ED-3C82-4D10-92ED-92E5B337E005Q38051718-D17C01BD-D8E8-4092-920F-4E62D9CCC4A4Q38059865-F5D3218F-FF51-4E33-93FD-89BE7024D4F1Q38116657-BC446C20-B3CB-4C4D-BC06-CE9244F11504Q38124439-D27DAFDC-94DE-4D7C-A7FF-A8F20F3575B7Q38156847-65B3AD02-7C4F-4382-AE9A-1BD344509526
P2860
Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Complete avoidance of calcineu ...... ring sirolimus and tacrolimus.
@en
Complete avoidance of calcineu ...... ring sirolimus and tacrolimus.
@nl
type
label
Complete avoidance of calcineu ...... ring sirolimus and tacrolimus.
@en
Complete avoidance of calcineu ...... ring sirolimus and tacrolimus.
@nl
prefLabel
Complete avoidance of calcineu ...... ring sirolimus and tacrolimus.
@en
Complete avoidance of calcineu ...... ring sirolimus and tacrolimus.
@nl
P2093
P2860
P1476
Complete avoidance of calcineu ...... ring sirolimus and tacrolimus.
@en
P2093
Griffin MD
Ishitani MB
Kremers WK
P2860
P304
P356
10.1111/J.1600-6143.2005.01177.X
P407
P577
2006-03-01T00:00:00Z